NEWS ALERTS KetoCytonyx/RenaSci collaboration produces promising new evidence About KetoCytonyx Inc About RenaSci Consultancy Ltd KetoCytonyx/RenaSci collaboration produces promising new evidence for neuroprotection with KTX 0101 Nottingham, UK, June 14, 2004 – RenaSci Consultancy Ltd, Nottingham, U.K. and KetoCytonyx Inc of West Conshohocken, PA, USA and London UK report the neuroprotective benefit of KTX 0101, the lead development candidate from KetoCytonyx, These are the first results from RenaSci’s scientific programme to support KetoCytonyx in the development of its clinical candidate, KTX 0101. (34th Annual Meeting of the Society for Neuroscience, San Diego, California, U.S.A., 23rd – 27th October 2004 (Abstract No. 2635)) KetoCytonyx was founded to develop specific ketones for the treatment of neurological disorders including ischaemia caused by major surgery, Parkinson’s and Alzheimer’s diseases. The scientific rationale for this approach is that ketone bodies, particularly D-ß-hydroxybutyrate, are used by the brain as alternative fuels to glucose under specific physiological conditions, including starvation. D-ß-Hydroxybutyrate, the most abundantly produced ketone in the body, has been shown to possess powerful neuroprotectant properties in a wide range of experimental situations including ischaemia, ischaemia/reperfusion injury, hypoxia, anoxia, Parkinson’s, Alzheimer’s and haemorrhagic shock. Moreover, it has long been known that a ketogenic diet (high in fat, low in carbohydrate) can reduce seizures in drug-resistant childhood epilepsy. Therefore, there is sound justification in support of the use of different forms of D-ß-hydroxybutyrate for acute and long-term neuroprotection in a wide range of neurological disorders. KetoCytonyx is about to enter Phase I development with KTX 0101 (sodium D-ß-hydroxybutyrate) as an intravenous neuroprotectant to prevent cognitive deficits caused by coronary bypass graft surgery. Return to Headlines About KetoCytonyx Inc KetoCytonyx, Inc. is a pharmaceutical product development company dedicated to providing metabolic therapeutics based on the manipulation of fundamental metabolic pathways to protect cells in a wide range of acute and chronic neurodegenerative conditions. Using its core ketone body technology, the company is currently focused on developing products for prevention of cognitive impairment following cardiothoracic and orthopaedic surgery and for disease modification/symptom reduction in Parkinson’s Disease with a new series of orally active compounds. KetoCytonyx was founded in November 2001 and closed Series A financing of $4.7 million from BTG, an intellectual property and technology commercialisation company, in March 2003. Professor Keith Martin, President and Chief Operating Officer of KetoCytonyx, said “The partnership with RenaSci is an important part of our development strategy. These new results support the view thatKTX 0101 has the potential to provide substantial neuroprotection against cognitive deficits caused by coronary bypass graft surgery. Although KTX 0101 is not suitable for long-term, oral use in its current formulation, these results are a fillip for our efforts to develop oral ketone modalities to treat neurological disorders including epilepsy, Parkinson’s and Alzheimer’s diseases”. For more information about KetoCytonyx, visit www.ketocytonyx.com Return to Headlines About RenaSci Consultancy Ltd RenaSci, formed in 2001, specialises in partnering large pharma, biotech and virtual pharmaceutical companies to provide consultancy advice and also to form strategic and experimental coalitions for the preclinical and clinical development of drugs. Its areas of expertise are in psychiatric and neurological disorders, as well as obesity and diabetes. One of its three Directors, Professor David Heal said “RenaSci is delighted to have been selected by KetoCytonyx to help support the development of KTX 0101 and their follow-on programmes. There is a wealth of data in the scientific literature demonstrating the neuroprotective benefits of ketone bodies. These new results are clinically significant because they show that the ketogenic diet to control childhood epilepsy may have the added benefit of also being neuroprotective when seizures do occur”. The partnership will publish its first results, “KTX 0101 Protects Hippocampal Neurones in an In Vitro Model of Status Epilepticus” (Abstract No. 2635), at the 34th Annual Meeting of the Society for Neuroscience in San Diego 23rd – 27th October 2004. For more information on these findings, visit our poster presentation at the meeting. Return to Headlines